An international study comparing conventional versus mRNA level testing (TargetPrint) for ER, PR, and HER2 status of breast cancer

Jelle Wesseling, Corrado Tinterri, Anna Sapino, Fabrizio Zanconati, Martijn Lutke-Holzik, Bichlien Nguyen, Kenneth B. Deck, Patrizia Querzoli, Tiziana Perin, Carmela Giardina, Gerhard Seitz, Jean Marc Guinebretière, Julie Barone, Laura Dekker, Femke de Snoo, Lisette Stork-Sloots, Paul Roepman, Toru Watanabe, Pino Cusumano

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

To compare results from messenger RNA (mRNA)-based TargetPrint testing with those from immunohistochemistry (IHC) and in situ hybridization (ISH) conducted according to local standard procedures at hospitals worldwide. Tumor samples were prospectively obtained from 806 patients at 22 hospitals. The mRNA level of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) was assessed by TargetPrint quantitative gene expression readouts. IHC/ISH assessments were performed according to local standards at the participating hospitals. TargetPrint readout showed a high concordance with IHC/ISH of 95 % (kappa 0.81) for ER, 81 % (kappa 0.56) for PR, and 94 % (kappa 0.76) for HER2. The positive/negative agreement between TargetPrint and IHC for ER, PR, and HER2 was 96 %/87 %, 84 %/74 %, and 74 %/98 %, respectively. The concordance rate in IHC/ISH results between hospitals varied: 88–100 % for ER (kappa 0.50–1.00); 50–100 % for PR (kappa 0.20–1.00); and 90–100 % for HER2 (kappa 0.59–1.00). mRNA readout of ER, PR, and HER2 status by TargetPrint was largely comparable to local IHC/ISH analysis. However, there was substantial discordance in IHC/ISH results between different hospitals. When results are discordant, the use of TargetPrint would improve the reliability of hormone receptor and HER2 results by prompting retesting in a reference laboratory.

Original languageEnglish
Pages (from-to)1-8
Number of pages8
JournalVirchows Archiv
DOIs
Publication statusAccepted/In press - Jul 4 2016

Fingerprint

Progesterone Receptors
Estrogen Receptors
In Situ Hybridization
Immunohistochemistry
Breast Neoplasms
Messenger RNA
human ERBB2 protein
Hormones
Gene Expression
Neoplasms

Keywords

  • Breast cancer
  • ER
  • Her-2
  • IHC/Fish
  • mRNA
  • PgR

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Cell Biology
  • Molecular Biology

Cite this

An international study comparing conventional versus mRNA level testing (TargetPrint) for ER, PR, and HER2 status of breast cancer. / Wesseling, Jelle; Tinterri, Corrado; Sapino, Anna; Zanconati, Fabrizio; Lutke-Holzik, Martijn; Nguyen, Bichlien; Deck, Kenneth B.; Querzoli, Patrizia; Perin, Tiziana; Giardina, Carmela; Seitz, Gerhard; Guinebretière, Jean Marc; Barone, Julie; Dekker, Laura; de Snoo, Femke; Stork-Sloots, Lisette; Roepman, Paul; Watanabe, Toru; Cusumano, Pino.

In: Virchows Archiv, 04.07.2016, p. 1-8.

Research output: Contribution to journalArticle

Wesseling, J, Tinterri, C, Sapino, A, Zanconati, F, Lutke-Holzik, M, Nguyen, B, Deck, KB, Querzoli, P, Perin, T, Giardina, C, Seitz, G, Guinebretière, JM, Barone, J, Dekker, L, de Snoo, F, Stork-Sloots, L, Roepman, P, Watanabe, T & Cusumano, P 2016, 'An international study comparing conventional versus mRNA level testing (TargetPrint) for ER, PR, and HER2 status of breast cancer', Virchows Archiv, pp. 1-8. https://doi.org/10.1007/s00428-016-1979-9
Wesseling, Jelle ; Tinterri, Corrado ; Sapino, Anna ; Zanconati, Fabrizio ; Lutke-Holzik, Martijn ; Nguyen, Bichlien ; Deck, Kenneth B. ; Querzoli, Patrizia ; Perin, Tiziana ; Giardina, Carmela ; Seitz, Gerhard ; Guinebretière, Jean Marc ; Barone, Julie ; Dekker, Laura ; de Snoo, Femke ; Stork-Sloots, Lisette ; Roepman, Paul ; Watanabe, Toru ; Cusumano, Pino. / An international study comparing conventional versus mRNA level testing (TargetPrint) for ER, PR, and HER2 status of breast cancer. In: Virchows Archiv. 2016 ; pp. 1-8.
@article{3a661d5ddb88490393a8f836badc9411,
title = "An international study comparing conventional versus mRNA level testing (TargetPrint) for ER, PR, and HER2 status of breast cancer",
abstract = "To compare results from messenger RNA (mRNA)-based TargetPrint testing with those from immunohistochemistry (IHC) and in situ hybridization (ISH) conducted according to local standard procedures at hospitals worldwide. Tumor samples were prospectively obtained from 806 patients at 22 hospitals. The mRNA level of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) was assessed by TargetPrint quantitative gene expression readouts. IHC/ISH assessments were performed according to local standards at the participating hospitals. TargetPrint readout showed a high concordance with IHC/ISH of 95 {\%} (kappa 0.81) for ER, 81 {\%} (kappa 0.56) for PR, and 94 {\%} (kappa 0.76) for HER2. The positive/negative agreement between TargetPrint and IHC for ER, PR, and HER2 was 96 {\%}/87 {\%}, 84 {\%}/74 {\%}, and 74 {\%}/98 {\%}, respectively. The concordance rate in IHC/ISH results between hospitals varied: 88–100 {\%} for ER (kappa 0.50–1.00); 50–100 {\%} for PR (kappa 0.20–1.00); and 90–100 {\%} for HER2 (kappa 0.59–1.00). mRNA readout of ER, PR, and HER2 status by TargetPrint was largely comparable to local IHC/ISH analysis. However, there was substantial discordance in IHC/ISH results between different hospitals. When results are discordant, the use of TargetPrint would improve the reliability of hormone receptor and HER2 results by prompting retesting in a reference laboratory.",
keywords = "Breast cancer, ER, Her-2, IHC/Fish, mRNA, PgR",
author = "Jelle Wesseling and Corrado Tinterri and Anna Sapino and Fabrizio Zanconati and Martijn Lutke-Holzik and Bichlien Nguyen and Deck, {Kenneth B.} and Patrizia Querzoli and Tiziana Perin and Carmela Giardina and Gerhard Seitz and Guinebreti{\`e}re, {Jean Marc} and Julie Barone and Laura Dekker and {de Snoo}, Femke and Lisette Stork-Sloots and Paul Roepman and Toru Watanabe and Pino Cusumano",
year = "2016",
month = "7",
day = "4",
doi = "10.1007/s00428-016-1979-9",
language = "English",
pages = "1--8",
journal = "Virchows Archiv - A Pathological Anatomy and Histopathology",
issn = "0945-6317",
publisher = "Springer Verlag",

}

TY - JOUR

T1 - An international study comparing conventional versus mRNA level testing (TargetPrint) for ER, PR, and HER2 status of breast cancer

AU - Wesseling, Jelle

AU - Tinterri, Corrado

AU - Sapino, Anna

AU - Zanconati, Fabrizio

AU - Lutke-Holzik, Martijn

AU - Nguyen, Bichlien

AU - Deck, Kenneth B.

AU - Querzoli, Patrizia

AU - Perin, Tiziana

AU - Giardina, Carmela

AU - Seitz, Gerhard

AU - Guinebretière, Jean Marc

AU - Barone, Julie

AU - Dekker, Laura

AU - de Snoo, Femke

AU - Stork-Sloots, Lisette

AU - Roepman, Paul

AU - Watanabe, Toru

AU - Cusumano, Pino

PY - 2016/7/4

Y1 - 2016/7/4

N2 - To compare results from messenger RNA (mRNA)-based TargetPrint testing with those from immunohistochemistry (IHC) and in situ hybridization (ISH) conducted according to local standard procedures at hospitals worldwide. Tumor samples were prospectively obtained from 806 patients at 22 hospitals. The mRNA level of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) was assessed by TargetPrint quantitative gene expression readouts. IHC/ISH assessments were performed according to local standards at the participating hospitals. TargetPrint readout showed a high concordance with IHC/ISH of 95 % (kappa 0.81) for ER, 81 % (kappa 0.56) for PR, and 94 % (kappa 0.76) for HER2. The positive/negative agreement between TargetPrint and IHC for ER, PR, and HER2 was 96 %/87 %, 84 %/74 %, and 74 %/98 %, respectively. The concordance rate in IHC/ISH results between hospitals varied: 88–100 % for ER (kappa 0.50–1.00); 50–100 % for PR (kappa 0.20–1.00); and 90–100 % for HER2 (kappa 0.59–1.00). mRNA readout of ER, PR, and HER2 status by TargetPrint was largely comparable to local IHC/ISH analysis. However, there was substantial discordance in IHC/ISH results between different hospitals. When results are discordant, the use of TargetPrint would improve the reliability of hormone receptor and HER2 results by prompting retesting in a reference laboratory.

AB - To compare results from messenger RNA (mRNA)-based TargetPrint testing with those from immunohistochemistry (IHC) and in situ hybridization (ISH) conducted according to local standard procedures at hospitals worldwide. Tumor samples were prospectively obtained from 806 patients at 22 hospitals. The mRNA level of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) was assessed by TargetPrint quantitative gene expression readouts. IHC/ISH assessments were performed according to local standards at the participating hospitals. TargetPrint readout showed a high concordance with IHC/ISH of 95 % (kappa 0.81) for ER, 81 % (kappa 0.56) for PR, and 94 % (kappa 0.76) for HER2. The positive/negative agreement between TargetPrint and IHC for ER, PR, and HER2 was 96 %/87 %, 84 %/74 %, and 74 %/98 %, respectively. The concordance rate in IHC/ISH results between hospitals varied: 88–100 % for ER (kappa 0.50–1.00); 50–100 % for PR (kappa 0.20–1.00); and 90–100 % for HER2 (kappa 0.59–1.00). mRNA readout of ER, PR, and HER2 status by TargetPrint was largely comparable to local IHC/ISH analysis. However, there was substantial discordance in IHC/ISH results between different hospitals. When results are discordant, the use of TargetPrint would improve the reliability of hormone receptor and HER2 results by prompting retesting in a reference laboratory.

KW - Breast cancer

KW - ER

KW - Her-2

KW - IHC/Fish

KW - mRNA

KW - PgR

UR - http://www.scopus.com/inward/record.url?scp=84976870319&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84976870319&partnerID=8YFLogxK

U2 - 10.1007/s00428-016-1979-9

DO - 10.1007/s00428-016-1979-9

M3 - Article

AN - SCOPUS:84976870319

SP - 1

EP - 8

JO - Virchows Archiv - A Pathological Anatomy and Histopathology

JF - Virchows Archiv - A Pathological Anatomy and Histopathology

SN - 0945-6317

ER -